A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma

The primary objective of this study is to compare the activity of raltitrexed and ZD1839 versus raltitrexed alone as second line chemotherapy in subjects with colorectal carcinoma by estimating progression free survival (PFS) in each treatment arm.

本研究的主要目的为对比雷替曲塞(raltitrexed)联合ZD1839与单用雷替曲塞作为结直肠癌受试者的二线化疗方案，通过评估各治疗组的无进展生存期(Progression Free Survival, PFS)，以比较二者的抗肿瘤活性。